AstraZeneca Brings Its Cell Therapy Ambitions to Maryland With $300M Plant Investment, 150 Planned Hires

Following a slew of cell therapy biotech team-ups, AstraZeneca is taking manufacturing into its own hands. The British pharma announced it will plug $300 million into a new facility in Rockville, Maryland, to launch its cell therapy platforms in the US for cancer trials and future commercial supply.